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CASE REPORTLong-Term Safety of Tedizolid in a Patient With
Spondilodiscitis After Switch From Linezolid Due to ToxicityRosa Maria Martínez Álvarez, MD, PhD,* Irene Navarro Pardo, BSc,†
Estela Moreno García, MD,* and Rafael Huarte Lacunza, BSc†Abstract: The patient is a 57-year-old man with liver cirrhosis, Bricker
anastomosis after a radical cystoprostatectomy and, a history of bacter-
emias caused by extended-spectrum β-lactamase–positive Escherichia
coli, Enterococcus faecium, and Candida albicans. He presented with
persistent low back pain and was diagnosed with vertebral osteomyelitis,
for which he received ertapenem-linezolid treatment. However, after
20 days, linezolid had to be discontinued because of myelotoxicity
and metabolic acidosis. The patient was switched to tedizolid, which, in
combination with ertapenem, was successfully given for 114 days until
biopsy showed no growth of gram-positive cocci. We conclude that
tedizolid can be an alternative to linezolid in case of toxicity, especially
in long-term treatments.
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Tedizolid phosphate is an inactive precursor (prodrug) ofoxazolidinone phosphate, which is active against gram-
positive pathogens. It is approved for the treatment of acute
bacterial skin and soft tissue infections caused by gram-positive
micro-organisms, including methicillin-resistant Staphylococcus
aureus. In addition, it showed in vitro activity against some atyp-
ical mycobacteria, atypical bacteria, and anaerobes.1
Linezolid, the first agent in the oxazolidinone group, has
been associated with certain adverse effects such as anemia,
thrombocytopenia, lactic acidosis, peripheral neuropathy, and op-
tic neuropathy, often linked to prolonged treatments. In pivotal
head-to-head clinical trials against linezolid, tedizolid was found
to have noninferior efficacy and a better safety profile in terms
of gastrointestinal adverse effects and platelet abnormalities.1,2
In a pooled safety data analysis from the two pivotal trials,3 a
lower incidence of thrombocytopenia among patients who re-
ceived tedizolid was observed, suggesting a potential clinical
toxicity difference that the authors suggested should be con-
firmed in longer-term trials. In both pivotal studies, no serious
adverse effects associated with long-term linezolid treatment,
such as myelosuppression, peripheral or optic neuropathy, or lac-
tic acidosis, were detected in tedizolid arms. It should be noted,
however, that tedizolid treatment duration in these studies was
only 6 days, which may have been not long enough to observe
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treated with tedizolid for a prolonged period after having dis-
continued linezolid because of hematological toxicity.CLINICAL CASE
The patient is a 57-year-old man with a history of crypto-
genic liver cirrhosis, Child-Pugh class C, with esophageal varices
and distal splenorenal shunt 8 years ago, awaiting liver transplan-
tation. He was diagnosed with bladder neoplasia and underwent
transurethral resection and subsequent radical cystoprostatectomy
with urinary diversion (Bricker technique); the postoperative
course was complicated by urologic sepsis with left pyelocaliceal
ectasia that required urgent nephrostomy and admission to the in-
tensive care unit for vasopressor support.
The intensive care unit stay was prolonged, with poor evolu-
tion complicated by bacteremias caused by extended-spectrum
β-lactamase–positive Escherichia coli, Enterococo faecium, and
Candida albicans, for which the patient received corresponding
targeted treatment. Six months later, he presented with low back
pain that had been lasting for a few weeks and could not be con-
trolled with usual analgesia. The patient had no fever; two com-
puted tomography scan images were compatible with vertebral
osteomyelitis at D9-D10 and L3-L4 vertebrae level. Blood cul-
tures were negative, and D9-D10 vertebral disc biopsy was per-
formed but not processed because of technical problems. In
view of the previous extended-spectrum β-lactamase–producing
E. coli and E. faecium bacteremias, it was decided to treat the ver-
tebral osteomyelitis with ertapenem and linezolid (requesting an
authorization for off-label use) to target these micro-organisms
as likely microbial agents.
In the first 20 days of antibiotic therapy, four units of red
blood cell concentrate had to be transfused to treat persistent ane-
mia without external bleeding: hemoglobin levels decreased from
baseline 9.3 g/dL to 7.8 g/dL on day 6 of linezolid treatment, after
which the first two units were transfused, and from 8.8 g/dL on
day 8 to 7.7 g/dL on day 13. The effect on the platelet count was
less pronounced, with a transient decrease to 84.000 cells/μL,
which quickly resolved and had no clinical consequences. So-
dium bicarbonate was used to treat normal anion gap metabolic
acidosis. Lactic acidosis was discarded; instead, these events were
interpreted as possible adverse effects of linezolid treatment and
urinary diversion in a patient with liver cirrhosis. Because of the
hematological toxicity, we requested an authorization to substitute
tedizolid (200 mg/24 h) for linezolid (600 mg/12 h). Although
both linezolid and tedizolid had been reported to cause hemato-
logical adverse effects, we have opted for a switch to tedizolid
based on the results of in vitro studies, tedizolid pharmacokinetic
profile, and few case reports that suggested possible differences in
mitochondrial toxicity and related adverse effects between the two
drugs (discussed hereinafter).
The patient needed two units of red blood cell concentrate on
the fourth day after the switch, after which the hematocrit level
stayed stable at approximately 30% without further transfusions2018 www.infectdis.com 1
thorized reproduction of this article is prohibited.
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though it could not be withdrawn until after several weeks after
the switch because of persistent symptomatic acidosis. The
tedizolid-ertapenem treatment was maintained for 114 days; at
this point, although Gram stain of tissue biopsy showed presence
of gram-positive cocci and yeast, the biopsy culture was posi-
tive only for C. albicans, for which a new targeted treatment
was initiated.DISCUSSION
Antibiotics of the oxazolidinone group, such as tedizolid and
linezolid, inhibit bacterial protein synthesis by binding to the
50S subunit of the prokaryotic ribosome but may also inhibit
mitochondrial protein synthesis due to the structural similari-
ties between the prokaryotic and the mitochondrial ribosomes.
Inhibition of mitochondrial ribosome is responsible for some ad-
verse effects, such as myelosuppression, lactic acidosis, and pe-
ripheral and ocular neuropathy. Although most of these adverse
effects are reversible, such toxicity may limit long-term use of
oxazolidinone drugs.2
Besides, in 2011 the FDA issued a safety communication
warning about possible serious CNS reactions associated with
the concomitant use of linezolid and certain psychiatric medica-
tions. Both tedizolid and linezolid were found to be weak and re-
versible inhibitors of monoamine oxidase (a mechanism that may
be behind the serotonergic syndrome). However, the higher anti-
microbial potency and longer half-life of tedizolid allow for a sin-
gle administration per day; besides, tedizolid's stronger binding to
plasma proteins and resulting lower free drug concentration as
well as minimal accumulation after several days of administration
decrease the risk of interaction with monoamine oxidase, com-
pared with linezolid.5,6
However, in vitro studies have shown that at therapeutic
doses, tedizolid is a more potent inhibitor of mitochondrial protein
synthesis than linezolid (dose- and time-dependent inhibition),
which is not surprising, given that tedizolid has additional targetFIGURE 1. Hemoglobin levels and platelet count during linezolid (grey)
performed on day 23. The arrows indicate time points of red blood cell
2 www.infectdis.com
Copyright © 2018 Wolters Kluwer Health, Inc. Unautbinding sites. Flanagan et al7 found a correlation between in-
creased linezolid trough concentrations (Cmin) and increased risk
of adverse effects, which was linked to the prolongedmaintenance
of Cmin above the concentration necessary to inhibit 50% of mito-
chondrial protein synthesis (IC50), without sufficient time for re-
covery of mitochondrial function between doses. In subsequent
analyzes, the authors observed that tedizolid had faster dissocia-
tion and recovery from mitochondrial damage, compared with
linezolid. The association between linezolid Cmin and mitochon-
drial toxicity also poses problems for prolonged treatments of
multidrug-resistant tuberculosis.8
The pharmacokinetic profile of tedizolid, which permits
once-daily administration of a therapeutic dose of 200mg (6 times
less than the 1200-mg daily dose of linezolid), could explain such
behavior. The time during which the free plasma concentration of
tedizolid remains above the IC50 is decreased, allowing for the re-
covery of mitochondrial function between doses.2,9,10 The free
plasma concentration of tedizolid 200 mg administered every
24 hours is estimated to stay below the IC50 for 8 hours, whereas
in case of linezolid 600 mg given every 12 hours, the free plasma
concentration of the drug is expected to be constantly above the
IC50. Therefore, exposure to linezolid does not permit mitochon-
drial function recovery, thus increasing the toxicity.3
Although linezolid does not require dose adjustment in
cases of hepatic or renal insufficiency, a greater risk of toxicity
has been observed in patients with severe renal or hepatic insuf-
ficiency treated with linezolid.11 Tedizolid is not eliminated with
urine, and although patients with renal or hepatic insufficiency
were not included in the pivotal trials, no pharmacokinetics or
safety profile issues were detected in patients with impaired re-
nal function or in those requiring long-term hemodialysis during
the phase 1 trials.3,10 In the phase 3 trials, where the maximum
tedizolid treatment duration was 6 days, the reported incidences
of peripheral neuropathy were similar in the two treatment arms
(1.2% and 0.6% for tedizolid phosphate and linezolid, re-
spectively). In these pivotal studies, the effects on hematologic pa-
rameters were reported for platelets, neutrophils, and hemoglobin,and tedizolid (black) treatment. The switch to tedizolid was
perfusions. PRBC, packed red blood cells.
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were observed for platelets. The percentages of patients with
hemoglobin levels below the lower limit of normal on days
7 to 9 were 29.4% and 33.3% in the tedizolid and linezolid
arms, respectively.12,13
There are few bibliographical references documenting the
switch from linezolid to tedizolid due to toxicity. We reviewed
the literature and found three articles describing long-term admin-
istration of tedizolid after linezolid-induced hematologic toxic-
ity.10,14,15 These articles reported a total of four cases, in one of
which tedizolid was given for 58 days and then withdrawn be-
cause of the decrease in hemoglobin levels, whereas in the other
three cases, no toxicity issues were observed for the 56, 88, and
180 days of tedizolid treatment (the latter case was of a patient
with multiple myeloma treated for nocardiosis).
In the case we describe, a transfusion was required in the first
week after the switch from linezolid to tedizolid because of the
low hemoglobin levels, but we attributed it to linezolid residual
toxicity. The hematologic tolerance in our case allowed for a pro-
longed antibiotic treatment (114 days) without incidents. As for
the acidosis, it is difficult to establish causality because it could
be either an adverse drug reaction or a complication of the urinary
diversion, given that metabolic acidosis occurs in 25% to 46% of
patients with urinary diversion, depending on the technique used
and the patient's renal function.16
Tedizolid may be considered as an alternative to linezolid in
case of recognized toxicities associated with mitochondrial dys-
function and a need for a long-term treatment.
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